Not surprisingly, increasing evidence suggests that the presence, location and density of both CD4+ and CD8+ lymphocytes in the tumor microenvironment of patients are primary drivers for productive anti-tumor immune responses and are predictors of overall survival 11-16. This evidence concerns the gene CD8A and neoplasm.